Non-interventional study of patients with PN NF1 starting selumetinib in Russia

Trial Identifier:	D1340R00002
Sponsor:	AstraZeneca
Start Date:	March 2023
Primary Completion Date:	July 2025
Study Completion Date:	July 2025

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

Country	Location
Russian Federation	Ekaterinburg, Russian Federation
Russian Federation	Moscow, Russian Federation
Russian Federation	Novosibirsk, Russian Federation
Russian Federation, Moskva	Moscow, Moskva, Russian Federation, 123112

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.